Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter
MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click: www.youtube.com/msviewsandnews
Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Tuesday, February 26, 2019
Sunday, February 24, 2019
Find a Cure Panel (FACP) specializes in patient research for rare and serious diseases and has some upcoming research for people with MS
This research focuses on your decision for which treatment you commenced (i.e. oral vs. injectable vs. infusion) as well as reasons for switching or potentially switching to another treatment and the decision calculus for such switch.
To qualify for this survey, you must meet the following qualifications:
- Have RRMS and be on oral (Aubagio, Gilenya, Tecfidera, etc.) or injectable (Avonex, Betaseron, Copaxone, Rebif, etc.). If you are on an infusion (Tysabri, Ocrevus) you will NOT qualify.
- Be on your first MS treatment unless you recently switched to a second treatment.
This research is very easy to participate in. It’s one call with one moderator talking about your experience.
FACP gives you a 1-800 number and schedules the call at your convenience and if you do the call, FACP will donate $200 to MS Views and News (MSVN).
If you are interested in participating, please email email@example.com (yes, this is a corrected email address) and reference MSVN.
President, Sample Czar
1850 Industrial Street, Suite 514
Los Angeles, CA 90021
MS Views and News is only providing the information for this research study.
We will not be involved in the activity nor the results.